share_log

FDA Gives Green Signal To Reviva Pharma's Late-Stage Schizophrenia Trial

FDA Gives Green Signal To Reviva Pharma's Late-Stage Schizophrenia Trial

FDA向Reviva Pharma的晚期精神分裂症试验发出绿色信号
Benzinga Real-time News ·  2022/01/10 07:16

The FDA has notified Reviva Pharmaceuticals Holdings Inc (NASDAQ:RVPH) that it may proceed with Phase 3 trial of its lead candidate, brilaroxazine, a serotonin and dopamine receptor modulator for schizophrenia.

FDA已经通知Reviva制药控股公司(Reviva PharmPharmticals Holdings Inc.)纳斯达克(Sequoia Capital：RVPH)宣布，该公司可能继续进行其主要候选药物BRilaroxazine的3期试验，Brilaroxazine是一种治疗精神分裂症的5-羟色胺和多巴胺受体调节剂。

  • The FDA has also signed off an additional Phase 3 trial focused on the long-term safety of brilaroxazine in patients with schizophrenia. 
  • Related: Reviva Pharma Stock Trading Higher On Detailed Positive Schizophrenia Study Results.
  • Both Phase 3 trials will be initiated simultaneously by the end of January 2022.
  • Price Action: RVPH shares are up 16.2% at $3.45 during the premarket session on the last check Monday.
  • FDA还批准了一项额外的3期试验，重点是布里拉沙嗪对精神分裂症患者的长期安全性。
  • 相关： Reviva Pharma股价因详细的阳性精神分裂症研究结果而走高.
  • 这两个阶段的第三阶段试验将在2022年1月底之前同时启动。
  • 价格行动：在周一最后一次检查的盘前交易中，RVPH股价上涨16.2%，至3.45美元。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发